Aliskiren
규격
173334-57-1CAS 번호
605-672-4EC 번호
(2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamideIUPAC 명칭
C30H53N3O6화학식
551.8 g/mol분자량
Aliskiren; 173334-57-1; SPP100; SPP 100; aliskirene; Aliskireno; SPP-100; CGP 60536; 502FWN4Q32; (2S,4S,5S,7S)-5-amino-N-(2-carbamoyl-2,2-dimethylethyl)-4-hydroxy-7-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-8-methyl-2-(propan-2-yl)nonanamide; CHEBI:601027; DTXSID40891494; CGP-060536B; CGP-60536; aliskirenum; (2S,4S,5S,7S)-5-amino-N-(2-carbamoyl-2,2-dimethylethyl)-4-hydroxy-7-((4-methoxy-3-(3-methoxypropoxy)phenyl)methyl)-8-methyl-2-(propan-2-yl)nonanamide; (2S,4S,5S,7S)-5-Amino-N-(2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonamide; (2S,4S,5S,7S)-5-Amino-N-(2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonamide; RefChem:56248; C09XA02; CGP060536B; DTXCID401030595; CGP60536; Aliskiren(CGP 60536); MFCD09839018; CHEMBL1639; CGP60536B; (2S,4S,5S,7S)-5-AMINO-N-(2-CARBAMOYL-2-METHYLPROPYL)-4-HYDROXY-2-ISOPROPYL-7-[4-METHOXY-3-(3-METHOXYPROPOXY)BENZYL]-8-METHYLNONANAMIDE; (2S,4S,5S,7S)-5-Amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonanamide; Benzeneoctanamide, delta-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis(1-methylethyl)-, (alphaS,gammaS,deltaS,zetaS)-; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(1-methylethyl)nonanamide; Benzeneoctanamide, delta-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis-(1-methylethyl)-, (alphaS,gammaS,deltaS,zetaS)-; Aliskiren [INN]; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxo-propyl)-4-hydroxy-2-isopropyl-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-nonanamide; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide; (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-2-(propan-2-yl)nonanamide; benzeneoctanamide, delta-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis(1-methylethyl)-, (alphaS,gammaS,deltaS,zetaS)-, fumarate; C30H53N3O6; NCGC00186464-01; CGP 60536;CGP60536B;SPP 100; Aliskiren [USAN:INN:BAN]; UNII-502FWN4Q32; Aliskiren?; HSDB 7843; (2S,4S,5S,7S)-5-amino-N-[2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide; Rasilez (TN); Aliskiren (Standard); Aliskiren-hemifumarate; ALISKIREN [MI]; Aliskiren (USAN/INN); ALISKIREN [HSDB]; ALISKIREN [USAN]; ALISKIREN [VANDF]; ALISKIREN [WHO-DD]; ALISKIREN [EMA EPAR]; SCHEMBL455490; GTPL4812; orb1704862; SCHEMBL29521564; BDBM17950; UXOWGYHJODZGMF-QORCZRPOSA-N; GLXC-05705; ALBB-027274; MSK11172; EBC-27307; HY-12176R; STL386835; AKOS015852572; AKOS015888741; CS-0443; DB09026; NCGC00186464-02; NCGC00186464-13; AS-80517; FA134549; HY-12176; SBI-0206888.P001; NS00007787; D03208; EN300-708809; T22233; AB01274865-01; AB01274865_02; AB01274865_03; F793779; Q414904; BRD-K30020243-051-01-7; BRD-K30020243-051-02-5; BRD-K30020243-051-03-3; (2S,4S,5S,7S)-5-Amino-N-(2-carbamoyl)-2-methylpropyl)-4-hydroxy-2-isopropyl-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-8-methylnonamide; (2S,4S,5S,7S)-5-Amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-8-methyl-2-(propan-2-yl)nonanamide; (2s,4s,5s,7s)-7-(4-methoxy-3-(3-methoxypropoxy)benzyl)-5-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-8-methylnonanamide; 1327153-71-8; 2(S),4(S),5(S),7(S)-N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-(4-methoxy-3-(3-methoxypropoxy)phenyl)octanamid hemifumarate; 5(S)-Amino-4(S)-hydroxy-2(S),7(S)-diisopropyl-8-[4-methoxy-3-(3-methoxypropyloxy)-phenyl]-octanoic acid N-(2-carbamoyl-2,2-dimethyl-ethyl)-amide; 5-Amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide fumar ate; Benzeneoctanamide, |A-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-|A-hydroxy-4-methoxy-3-(3-methoxypropoxy)-|A,|AE-bis(1-methylethyl)-, (|AS,|AS,|AS,|AES)-; benzeneoctanamide, delta-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-gamma-hydroxy-4-methoxy-3-(3-methoxypropoxy)-alpha,zeta-bis(1-me thylethyl)-, (alphaS,gammaS,deltaS,zetaS)-, fumarate; C41동의어
Aliskiren 함유 제품
RASILEZ 300 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 300 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 300 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 300 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 300 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 150 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 150 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 150 mg COMPRIMIDOS RECUBIERTOS CON PELICULARASILEZ 150 mg COMPRIMIDOS RECUBIERTOS CON PELICULAAliskirenAliskirenAliskiren